US biotechnology company Moderna announced that its Covid-19 vaccine will be effective against the new variants of coronavirus identified in the United Kingdom and South Africa.

Moderna says its jab is effective against UK & South Africa strains

Moderna Inc said on Monday it believes its COVID-19 vaccine protects against new variants found in Britain and South Africa, although it will test a new booster shot aimed at the South African variant after concluding the antibody response could be diminished.

Moderna says it believes vaccine will work against new variants

The US firm Moderna has claimed their vaccine is effective against the new strain of coronavirus found in the UK and South Africa.

Recent lab reports have shown that Moderna's COVID-19 vaccine gives protection against the deadly virus' new variants too.

Also read|&nbsp;<a href="https://www.wionews.com/world/us-study-finds-adverse-reactions-to-moderna-vaccine-are-rare-358746">US study finds adverse reactions to Moderna vaccine are rare</a>

This has come as welcoming news as several countries have reported multiple cases of the new variants, and many have also reported a surge in cases due to the new strains.

"The study showed no significant impact" on the level of neutralizing antibodies elicited against the UK variant, B.1.1.7.

Also read:&nbsp;<a href="http://13.235.153.162/world/heres-how-long-modernas-vaccine-will-protect-you-from-coronavirus-356272" hreflang="en">Here's how long Moderna's vaccine will protect you from coronavirus</a>

A six-fold reduction in antibody levels was observed with the B.1.351 variant first seen in South Africa, but the levels are thought to remain above what is required for protection against COVID-19.

This news has also come at a time when the Pfizer-BioNTech vaccine has been facing criticism for delaying the vaccine doses, especially in the EU countries. Pfizer has claimed that a minor delay has been caused in the delivery due to some construction issues in one of their facilities.

(With inputs from agencies)

The US firm Moderna has claimed their vaccine is effective against the new strain of coronavirus found in the UK and South Africa. Recent lab reports have shown that Moderna's COVID-19 vaccine gives protection against the deadly virus' new variants too.

The US firm Moderna has claimed their vaccine is effective against the new strain of coronavirus found in the UK and South Africa. Recent lab reports have shown that Moderna's COVID-19 vaccine gives protection against the deadly virus' new variants too. Also read| US study finds adverse reactions to Moderna vaccine are rare This has come as welcoming news as several countries have reported multiple cases of the new variants, and many have also reported a surge in cases due to the new strains. "The study showed no significant impact" on the level of neutralizing antibodies elicited against the UK variant, B.1.1.7. Also read: Here's how long Moderna's vaccine will protect you from coronavirus A six-fold reduction in antibody levels was observed with the B.1.351 variant first seen in South Africa, but the levels are thought to remain above what is required for protection against COVID-19. This news has also come at a time when the Pfizer-BioNTech vaccine has been facing criticism for delaying the vaccine doses, especially in the EU countries. Pfizer has claimed that a minor delay has been caused in the delivery due to some construction issues in one of their facilities. (With inputs from agencies)

Moderna vaccine effective against UK and South Africa coronavirus variant

A study from the United States found that severe allergic reactions to Moderna's COVID-19 vaccine is "rare". US health authorities claimed that only 10 cases of severe reactions arose among four million first doses.

The US Centers for Disease Control and Prevention added that widespread vaccination was critical in fighting the pandemic.

"Based on this early monitoring, anaphylaxis after receipt of Moderna Covid-19 vaccine appears to be a rare event," the CDC said in a report.

No deaths were reported in adverse reactions.

As per CDC data, ten cases of anaphylactic shock were recorded among 4,041,396 first doses of the vaccine, which were administered between December 21 and January 10.

The CDC added that six cases required hospitalisation, while four were treated in an emergency setting.

Also read:&nbsp;<a href="http://13.235.153.162/world/heres-how-long-modernas-vaccine-will-protect-you-from-coronavirus-356272" hreflang="en">Here's how long Moderna's vaccine will protect you from coronavirus</a>

Based on the numbers, 2.5 cases of anaphylactic shock were recorded for every million of Moderna injections, when compared to 11.1 cases per one million Pfizer vaccinations.

"The clinical and epidemiologic characteristics of anaphylaxis case reports after receipt of Moderna Covid-19 vaccine are similar to those reported after receipt of the Pfizer-BioNTech Covid-19 vaccine," the report said.

Also read:&nbsp;<a href="http://13.235.153.162/world/california-pauses-use-of-moderna-vaccine-batch-over-allergic-reactions-357470" hreflang="en">California pauses use of Moderna vaccine batch over allergic reactions</a>

All 10 severe reactions were recorded among women aged between 31 and 63. Out of these, nine had a history of allergic reaction, but even then not to vaccines.

A higher ratio of severe reactions was also recorded in data from Pfizer's vaccine. Experts believe this could be due to more women receiving the vaccinations as compared to men. 
&nbsp;

A study from the United States found that severe allergic reactions to Moderna's COVID-19 vaccine is "rare". US health authorities claimed that only 10 cases of severe reactions arose among four million first doses.

A study from the United States found that severe allergic reactions to Moderna's COVID-19 vaccine is "rare". US health authorities claimed that only 10 cases of severe reactions arose among four million first doses. The US Centers for Disease Control and Prevention added that widespread vaccination was critical in fighting the pandemic. "Based on this early monitoring, anaphylaxis after receipt of Moderna Covid-19 vaccine appears to be a rare event," the CDC said in a report. No deaths were reported in adverse reactions. As per CDC data, ten cases of anaphylactic shock were recorded among 4,041,396 first doses of the vaccine, which were administered between December 21 and January 10. The CDC added that six cases required hospitalisation, while four were treated in an emergency setting. Also read: Here's how long Moderna's vaccine will protect you from coronavirus Based on the numbers, 2.5 cases of anaphylactic shock were recorded for every million of Moderna injections, when compared to 11.1 cases per one million Pfizer vaccinations. "The clinical and epidemiologic characteristics of anaphylaxis case reports after receipt of Moderna Covid-19 vaccine are similar to those reported after receipt of the Pfizer-BioNTech Covid-19 vaccine," the report said. Also read: California pauses use of Moderna vaccine batch over allergic reactions All 10 severe reactions were recorded among women aged between 31 and 63. Out of these, nine had a history of allergic reaction, but even then not to vaccines. A higher ratio of severe reactions was also recorded in data from Pfizer's vaccine. Experts believe this could be due to more women receiving the vaccinations as compared to men.

US study finds adverse reactions to Moderna vaccine  are rare

UK on Friday approved coronavirus vaccine developed by Moderna for mass inoculation. This is a third vaccine that has got a go-ahead in UK. The government is aiming to incolute 15 million by mid-February. 1.5 million people have been given doses of Pfizer-BioNTech or Oxford-Astrazeneca vaccines since Decemeber.

Go ahead to the Moderna vaccine was given by the independent Medicines and Healthcare products Regulatory Agency (MHRA)

UK Health Secretary Matt Hancock welcomed the development and said that the approval was another shot in the arm for UK's vaccination programme.

"Moderna's vaccine will allow us to accelerate our vaccination programme even further once doses become available from the spring."

The MHRA was the first regulator in the world to approve the Pfizer-BioNTech and Oxford-AstraZeneca jabs, allowing the start of what health chiefs said is Britain's biggest-ever vaccination drive.

Hancock's department said the Moderna jab "meets the regulator's strict standards of safety, efficacy and quality".

Its authorisation follows months of clinical trials involving tens of thousands of people, and extensive analysis of its safety, quality and effectiveness.

England's deputy chief medical officer, Jonathan Van-Tam, called the vaccine "highly effective" and said it was "another impressive success for science".

The Department of Health and Social Care said it was 94 percent effective in preventing disease, including in the elderly.

Britain has ordered 17 million doses of the vaccine, which will be delivered in the coming months once Moderna increases production capacity, it added.

Elderly residents and staff at care homes, the over-70s and the clinically extremely vulnerable are first in line for the jabs, and the government has stepped up the programme to meet its February target.

More than 1,000 new vaccination sites, including in community pharmacies and even supermarket car parks, are expected to be open by the end of this week.

Army logistics specialists have been drafted in to help with supply and deliveries.

Britain has secured early access to 367 million doses of seven of the most promising vaccine candidates.

The Moderna announcement comes with much of Britain under a renewed lockdown to try to cut spiralling infection rates and deaths blamed on a fast-spreading variant of the virus.

A total of 1,162 new deaths within 28 days of a positive test were recorded on Thursday -- the highest since the first-wave peak in April last year.

Overall, some 2.9 million people have been infected.

Stay-at-home restrictions, which include school closures, are expected to last until at least mid-February.

"This is further great news and another weapon in our arsenal to tame this awful disease," he said.

"Moderna's vaccine will allow us to accelerate our vaccination programme even further once doses become available from the spring."

The MHRA was the first regulator in the world to approve the Pfizer-BioNTech and Oxford-AstraZeneca jabs, allowing the start of what health chiefs said is Britain's biggest-ever vaccination drive.

Hancock's department said the Moderna jab "meets the regulator's strict standards of safety, efficacy and quality".

Its authorisation follows months of clinical trials involving tens of thousands of people, and extensive analysis of its safety, quality and effectiveness.

England's deputy chief medical officer, Jonathan Van-Tam, called the vaccine "highly effective" and said it was "another impressive success for science".

The Department of Health and Social Care said it was 94 percent effective in preventing disease, including in the elderly.

Britain has ordered 17 million doses of the vaccine, which will be delivered in the coming months once Moderna increases production capacity, it added.

Elderly residents and staff at care homes, the over-70s and the clinically extremely vulnerable are first in line for the jabs, and the government has stepped up the programme to meet its February target.

More than 1,000 new vaccination sites, including in community pharmacies and even supermarket car parks, are expected to be open by the end of this week.

Army logistics specialists have been drafted in to help with supply and deliveries.

Britain has secured early access to 367 million doses of seven of the most promising vaccine candidates.

The Moderna announcement comes with much of Britain under a renewed lockdown to try to cut spiralling infection rates and deaths blamed on a fast-spreading variant of the virus.

A total of 1,162 new deaths within 28 days of a positive test were recorded on Thursday -- the highest since the first-wave peak in April last year. 
Overall, some 2.9 million people have been infected.

Stay-at-home restrictions, which include school closures, are expected to last until at least mid-February.

(With AFP inputs)

UK on Friday approved coronavirus vaccine developed by Moderna for mass inoculation. This is a third vaccine that has got a go-ahead in UK. The government is aiming to incolute 15 million by mid-February.

UK on Friday approved coronavirus vaccine developed by Moderna for mass inoculation. This is a third vaccine that has got a go-ahead in UK. The government is aiming to incolute 15 million by mid-February. 1.5 million people have been given doses of Pfizer-BioNTech or Oxford-Astrazeneca vaccines since Decemeber. Go ahead to the Moderna vaccine was given by the independent Medicines and Healthcare products Regulatory Agency (MHRA) UK Health Secretary Matt Hancock welcomed the development and said that the approval was another shot in the arm for UK's vaccination programme. "Moderna's vaccine will allow us to accelerate our vaccination programme even further once doses become available from the spring." The MHRA was the first regulator in the world to approve the Pfizer-BioNTech and Oxford-AstraZeneca jabs, allowing the start of what health chiefs said is Britain's biggest-ever vaccination drive. Hancock's department said the Moderna jab "meets the regulator's strict standards of safety, efficacy and quality". Its authorisation follows months of clinical trials involving tens of thousands of people, and extensive analysis of its safety, quality and effectiveness. England's deputy chief medical officer, Jonathan Van-Tam, called the vaccine "highly effective" and said it was "another impressive success for science". The Department of Health and Social Care said it was 94 percent effective in preventing disease, including in the elderly. Britain has ordered 17 million doses of the vaccine, which will be delivered in the coming months once Moderna increases production capacity, it added. Elderly residents and staff at care homes, the over-70s and the clinically extremely vulnerable are first in line for the jabs, and the government has stepped up the programme to meet its February target. More than 1,000 new vaccination sites, including in community pharmacies and even supermarket car parks, are expected to be open by the end of this week. Army logistics specialists have been drafted in to help with supply and deliveries. Britain has secured early access to 367 million doses of seven of the most promising vaccine candidates. The Moderna announcement comes with much of Britain under a renewed lockdown to try to cut spiralling infection rates and deaths blamed on a fast-spreading variant of the virus. A total of 1,162 new deaths within 28 days of a positive test were recorded on Thursday -- the highest since the first-wave peak in April last year. Overall, some 2.9 million people have been infected. Stay-at-home restrictions, which include school closures, are expected to last until at least mid-February. "This is further great news and another weapon in our arsenal to tame this awful disease," he said. "Moderna's vaccine will allow us to accelerate our vaccination programme even further once doses become available from the spring." The MHRA was the first regulator in the world to approve the Pfizer-BioNTech and Oxford-AstraZeneca jabs, allowing the start of what health chiefs said is Britain's biggest-ever vaccination drive. Hancock's department said the Moderna jab "meets the regulator's strict standards of safety, efficacy and quality". Its authorisation follows months of clinical trials involving tens of thousands of people, and extensive analysis of its safety, quality and effectiveness. England's deputy chief medical officer, Jonathan Van-Tam, called the vaccine "highly effective" and said it was "another impressive success for science". The Department of Health and Social Care said it was 94 percent effective in preventing disease, including in the elderly. Britain has ordered 17 million doses of the vaccine, which will be delivered in the coming months once Moderna increases production capacity, it added. Elderly residents and staff at care homes, the over-70s and the clinically extremely vulnerable are first in line for the jabs, and the government has stepped up the programme to meet its February target. More than 1,000 new vaccination sites, including in community pharmacies and even supermarket car parks, are expected to be open by the end of this week. Army logistics specialists have been drafted in to help with supply and deliveries. Britain has secured early access to 367 million doses of seven of the most promising vaccine candidates. The Moderna announcement comes with much of Britain under a renewed lockdown to try to cut spiralling infection rates and deaths blamed on a fast-spreading variant of the virus. A total of 1,162 new deaths within 28 days of a positive test were recorded on Thursday -- the highest since the first-wave peak in April last year. Overall, some 2.9 million people have been infected. Stay-at-home restrictions, which include school closures, are expected to last until at least mid-February. (With AFP inputs)

Moderna COVID vaccine gets approval in UK

The United States government may cut the dose of Moderna's coronavirus vaccine in half for some&nbsp;in a bid to inoculate more people and to speed up vaccinations.

On Sunday, Moncef Slaoui, head of Operation Warp Speed, the US government's programme for the emergency rollout of vaccines announced plans to halve the dose of Moderna's vaccines.

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/moderna-starts-shipping-its-covid-19-vaccine-in-us-351277/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

On CBS, Slaoui said that they were in talks with Moderna and the Food and Drug Administration (FDA) about the idea.

As of now, Moderna's vaccine requires two injections, but this could change.

Also read:&nbsp;<a href="http://13.235.153.162/world/wisconsin-pharmacist-arrested-for-removing-500-doses-of-moderna-covid-19-vaccine-353792" hreflang="en">Wisconsin pharmacist arrested for removing 500 doses of Moderna COVID-19 vaccine</a>

"We know that for the Moderna vaccine, giving half of the dose to people between the ages of 18 and 55, two doses, half the dose, which means exactly achieving the objective of immunizing double the number of people with the doses we have," Slaoui said.

"We know it induces identical immune response", he added. According to the US Centers for Disease Control and Prevention, the country has administered 4,22,756 doses of COVID-19 vaccines as of Saturday morning. Additionally, the country had distributed 13,071,925 doses of the vaccine.

Also read:&nbsp;<a href="http://13.235.153.162/world/boston-doctor-develops-severe-allergic-reaction-to-moderna-covid-vaccine-352464" hreflang="en">Boston doctor develops severe allergic reaction to Moderna COVID vaccine</a>

In addition to Moderna's vaccine, the US has also approved a vaccine from Pfizer, which also requires two shots. Even then, the goal of mass inoculation has fallen short. By the end of 2020, officials had hoped to vaccinate 20 million people. 
 
Slaoui further claimed that he expected the number of vaccinations to continue going up. In addition, he rejected the suggestion that officials should focus more on giving people the first shot, instead of holding back doses to complete the regimen. He added how cutting Moderna's vaccine in half was a ''more responsible approach'' based on facts and data.

The United States government may cut the dose of Moderna's coronavirus vaccine in half for some in a bid to inoculate more people and to speed up vaccinations. On Sunday, Moncef Slaoui, head of Operation Warp Speed, the US government's programme for the emergency rollout of vaccines announced plans to halve the dose of Moderna's vaccines.

The United States government may cut the dose of Moderna's coronavirus vaccine in half for some in a bid to inoculate more people and to speed up vaccinations. On Sunday, Moncef Slaoui, head of Operation Warp Speed, the US government's programme for the emergency rollout of vaccines announced plans to halve the dose of Moderna's vaccines. On CBS, Slaoui said that they were in talks with Moderna and the Food and Drug Administration (FDA) about the idea. As of now, Moderna's vaccine requires two injections, but this could change. Also read: Wisconsin pharmacist arrested for removing 500 doses of Moderna COVID-19 vaccine "We know that for the Moderna vaccine, giving half of the dose to people between the ages of 18 and 55, two doses, half the dose, which means exactly achieving the objective of immunizing double the number of people with the doses we have," Slaoui said. "We know it induces identical immune response", he added. According to the US Centers for Disease Control and Prevention, the country has administered 4,22,756 doses of COVID-19 vaccines as of Saturday morning. Additionally, the country had distributed 13,071,925 doses of the vaccine. Also read: Boston doctor develops severe allergic reaction to Moderna COVID vaccine In addition to Moderna's vaccine, the US has also approved a vaccine from Pfizer, which also requires two shots. Even then, the goal of mass inoculation has fallen short. By the end of 2020, officials had hoped to vaccinate 20 million people. Slaoui further claimed that he expected the number of vaccinations to continue going up. In addition, he rejected the suggestion that officials should focus more on giving people the first shot, instead of holding back doses to complete the regimen. He added how cutting Moderna's vaccine in half was a ''more responsible approach'' based on facts and data.

US may halve Moderna's vaccine doses to inoculate more people

In Phase 1a of the vaccine rollout, health care workers and residents of long-term care facilities are prioritized.

U.S. vaccination dilemma: No clarity on how essential workers will be verified

Canada has received the first batch of the coronavirus vaccine from Moderna just one day after the government`s approval, Canadian Prime Minister Justin Trudeau said.On Wednesday, the national agency Health Canada authorised the use of the Moderna vaccine against the COVID-19 virus in the country`s immunisation campaign.

"The first doses of Moderna`s COVID-19 vaccine have arrived in Canada. These are part of the 168,000 doses we will be getting before the end of the month, and part of the 40 million doses we are guaranteed from Moderna overall," Trudeau tweeted late on Thursday.

According to Public Services Minister Anita Anand, these vaccine batches would be the first to be deployed to the country`s north.Apart from the Moderna vaccine, Canada has secured up to 20 million doses of the Pfizer vaccine against the coronavirus, expecting 1.2 million doses from both manufactures to be delivered to the country by the end of next month.The government expects to vaccinate up to three million of its citizens in early 2021.

Canada has received the first batch of the coronavirus vaccine from Moderna just one day after the government`s approval, Canadian Prime Minister Justin Trudeau said.

Canada has received the first batch of the coronavirus vaccine from Moderna just one day after the government`s approval, Canadian Prime Minister Justin Trudeau said.On Wednesday, the national agency Health Canada authorised the use of the Moderna vaccine against the COVID-19 virus in the country`s immunisation campaign. "The first doses of Moderna`s COVID-19 vaccine have arrived in Canada. These are part of the 168,000 doses we will be getting before the end of the month, and part of the 40 million doses we are guaranteed from Moderna overall," Trudeau tweeted late on Thursday. According to Public Services Minister Anita Anand, these vaccine batches would be the first to be deployed to the country`s north.Apart from the Moderna vaccine, Canada has secured up to 20 million doses of the Pfizer vaccine against the coronavirus, expecting 1.2 million doses from both manufactures to be delivered to the country by the end of next month.The government expects to vaccinate up to three million of its citizens in early 2021.

Canada gets first batch of 168,000 Moderna COVID-19 vaccine doses

Moderna Inc said it expects that the immunity induced by its COVID-19 vaccine would be protective against the coronavirus variants reported in the UK.

The company said it plans to run tests to confirm the vaccine's activity against any strain.

Moderna's comments came amid the British government's plan to place huge swathes of England under its strictest COVID-19 restrictions as a highly infectious virus variant sweeps the country.

The company said it expects its vaccine, which was recently granted the U.S. emergency use authorization, to be protective against the UK variant based on data to date.

"We have already tested sera from animals and humans vaccinated with the Moderna COVID-19 Vaccine against a number of previous variants of the SARS-CoV-2 virus that have emerged since the first outbreak of the pandemic and found our vaccine to remain equally effective," Moderna said.

The US-based company said it would be performing additional tests of the vaccine in the coming weeks to confirm its expectation.

Moderna Inc said it expects that the immunity induced by its COVID-19 vaccine would be protective against the coronavirus variants reported in the UK. The company said it plans to run tests to confirm the vaccine's activity against any strain.

Moderna Inc said it expects that the immunity induced by its COVID-19 vaccine would be protective against the coronavirus variants reported in the UK. The company said it plans to run tests to confirm the vaccine's activity against any strain. Moderna's comments came amid the British government's plan to place huge swathes of England under its strictest COVID-19 restrictions as a highly infectious virus variant sweeps the country. The company said it expects its vaccine, which was recently granted the U.S. emergency use authorization, to be protective against the UK variant based on data to date. "We have already tested sera from animals and humans vaccinated with the Moderna COVID-19 Vaccine against a number of previous variants of the SARS-CoV-2 virus that have emerged since the first outbreak of the pandemic and found our vaccine to remain equally effective," Moderna said. The US-based company said it would be performing additional tests of the vaccine in the coming weeks to confirm its expectation.

Moderna expects its COVID-19 vaccine to protect against UK coronavirus variant

Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant.

Can new vaccines take on Covid mutation?

&nbsp;

In another historic moment, the US administered first&nbsp;Moderna Inc's <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine</a> to a&nbsp;nurse at a hospital in Connecticut on Monday.

Mandy Delgado works as a nurse for the Hartford Healthcare hospital. She was administered a shot of the Moderna vaccine&nbsp;around 11:40 am (1640 GMT), according to a live feed of the event.

Also&nbsp;watch: <a href="https://www.wionews.com/world/watch-us-nurse-passes-out-after-getting-pfizer-biontechs-covid-19-vaccine-350712">US nurse passes out after getting Pfizer-BioNTech’s COVID-19 vaccine</a>

"I am excited. I feel privileged," she said after getting the shot of the vaccine against the novel coronavirus. Her enthusiasm and courage were met with a round of applause by the people around her.

The shot has been administered a few days after the Moderna vaccine became the second in the US to receive&nbsp;emergency use authorization (EUA) from the US&nbsp;Food and Drug Administration (FDA), with the first one being&nbsp;Pfizer-Biotech's vaccine.

The Moderna vaccine can be stored at -20 degrees Celsius (-4 degrees Fahrenheit), much lower than Pfizer's vaccine which must be stored at -70 degrees Celsius (-94 degrees Fahrenheit), making it easier to distribute.

Have a look|&nbsp;<a href="https://www.wionews.com/photos/the-truth-about-coronavirus-vaccines-8-myths-busted-351294">The truth about coronavirus vaccines - 8 myths busted!</a>

Local authorities are hoping these vaccines will be able to contain the widespread of the novel coronavirus, which has affected the US in the worst way.

"With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,"&nbsp;FDA Commissioner Stephen M. Hahn, M.D, said in a statement.

In another historic moment, the US administered first Moderna Inc's coronavirus vaccine to a nurse at a hospital in Connecticut on Monday. Mandy Delgado works as a nurse for the Hartford Healthcare hospital.

In another historic moment, the US administered first Moderna Inc's coronavirus vaccine to a nurse at a hospital in Connecticut on Monday. Mandy Delgado works as a nurse for the Hartford Healthcare hospital. She was administered a shot of the Moderna vaccine around 11:40 am (1640 GMT), according to a live feed of the event. Also watch: US nurse passes out after getting Pfizer-BioNTech’s COVID-19 vaccine "I am excited. I feel privileged," she said after getting the shot of the vaccine against the novel coronavirus. Her enthusiasm and courage were met with a round of applause by the people around her. The shot has been administered a few days after the Moderna vaccine became the second in the US to receive emergency use authorization (EUA) from the US Food and Drug Administration (FDA), with the first one being Pfizer-Biotech's vaccine. The Moderna vaccine can be stored at -20 degrees Celsius (-4 degrees Fahrenheit), much lower than Pfizer's vaccine which must be stored at -70 degrees Celsius (-94 degrees Fahrenheit), making it easier to distribute. Have a look| The truth about coronavirus vaccines - 8 myths busted! Local authorities are hoping these vaccines will be able to contain the widespread of the novel coronavirus, which has affected the US in the worst way. "With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day," FDA Commissioner Stephen M. Hahn, M.D, said in a statement.

Another milestone: US administers first Moderna COVID-19 vaccines

On Sunday the advisory committee recommended states should put adults over 75 and “essential workers” next in line, as bus drivers, grocery store clerks and others are infected most often.

Moderna starts shipping its COVID-19 vaccine in U.S.

The US Centers for Disease Control and Prevention (CDC) has said it is monitoring reports of allergic reactions to the COVID-19 vaccination and made recommendations on how people with histories of allergies should proceed.

The agency defined severe as needing the medication epinephrine or treatment in a hospital, adding that anyone who had a severe reaction to a COVID-19 vaccine should not get the second dose.

People who have had a severe allergic reaction to any ingredient in a COVID-19 vaccine should avoid the vaccine formulation containing the ingredient, CDC said. Two vaccines have been approved in the United States under emergency use authorisations.

Individuals with histories of severe allergic reaction to vaccines should consult their doctors about the COVID-19 shot. The CDC said people with severe allergies to food, pets, latex or environmental conditions as well as people with allergies to oral medication or a family history of severe allergic reactions could still get vaccinated.

Britain's medical regulator has said that anyone with a history of anaphylaxis, or severe allergic reactions to a medicine or food, should not be given the Pfizer-BioNTech COVID-19 vaccine.

It was earlier reported that the US Food and Drug Administration (FDA) is investigating around five allergic reactions that happened after people were administered Pfizer Inc and BioNTech SE's COVID-19 vaccine in the United States this week.

On Friday, the FDA said that the Moderna Inc vaccine, which received emergency use authorization, should not be given to individuals with a known history of a severe allergic reaction to any components of the shot.

The US Centers for Disease Control and Prevention (CDC) has said it is monitoring reports of allergic reactions to the COVID-19 vaccination and made recommendations on how people with histories of allergies should proceed.

The US Centers for Disease Control and Prevention (CDC) has said it is monitoring reports of allergic reactions to the COVID-19 vaccination and made recommendations on how people with histories of allergies should proceed. The agency defined severe as needing the medication epinephrine or treatment in a hospital, adding that anyone who had a severe reaction to a COVID-19 vaccine should not get the second dose. People who have had a severe allergic reaction to any ingredient in a COVID-19 vaccine should avoid the vaccine formulation containing the ingredient, CDC said. Two vaccines have been approved in the United States under emergency use authorisations. Individuals with histories of severe allergic reaction to vaccines should consult their doctors about the COVID-19 shot. The CDC said people with severe allergies to food, pets, latex or environmental conditions as well as people with allergies to oral medication or a family history of severe allergic reactions could still get vaccinated. Britain's medical regulator has said that anyone with a history of anaphylaxis, or severe allergic reactions to a medicine or food, should not be given the Pfizer-BioNTech COVID-19 vaccine. It was earlier reported that the US Food and Drug Administration (FDA) is investigating around five allergic reactions that happened after people were administered Pfizer Inc and BioNTech SE's COVID-19 vaccine in the United States this week. On Friday, the FDA said that the Moderna Inc vaccine, which received emergency use authorization, should not be given to individuals with a known history of a severe allergic reaction to any components of the shot.

US CDC issues guidelines on Covid vaccination after allergic reactions

The US Federal Aviation Administration (FAA) has approved the use of the Moderna COVID-19 vaccine by pilots and air traffic controllers.

The Saturday announcement follows the FAA's December 12 approval for pilots and controllers to use the vaccine from Pfizer and BioNTech.

The US aviation regulator said pilots and controllers must not fly or conduct safety-related duties for 48 hours after receiving doses.&nbsp;

It said it "will monitor the patient response to each vaccine dose and may adjust this policy as necessary to ensure aviation safety."

On Thursday, groups representing aviation unions and American Airlines, United Airlines, Delta Air Lines and other airlines, wrote to all US governors asking them to "prioritise aviation frontline workers for allocation of the vaccine in your upcoming implementation plan."

The groups noted that "aviation workers are frontline workers who either encounter the traveling public frequently or are required to perform our work in close proximity to our colleagues and perform our jobs onsite."

Earlier this month, the FAA sent guidance to airports to prepare for vaccine distribution, including other facilities that may serve as alternate or diversion airports.

The FAA said that some aircraft used for vaccine shipments may be larger than the aircraft used for passenger-carrying flights that typically serve that airport and operators may opt to have extra aircraft rescue and firefighting services.

(with inputs)

The US Federal Aviation Administration (FAA) has approved the use of the Moderna COVID-19 vaccine by pilots and air traffic controllers. The Saturday announcement follows the FAA's December 12 approval for pilots and controllers to use the vaccine from Pfizer and BioNTech.

The US Federal Aviation Administration (FAA) has approved the use of the Moderna COVID-19 vaccine by pilots and air traffic controllers. The Saturday announcement follows the FAA's December 12 approval for pilots and controllers to use the vaccine from Pfizer and BioNTech. The US aviation regulator said pilots and controllers must not fly or conduct safety-related duties for 48 hours after receiving doses. It said it "will monitor the patient response to each vaccine dose and may adjust this policy as necessary to ensure aviation safety." On Thursday, groups representing aviation unions and American Airlines, United Airlines, Delta Air Lines and other airlines, wrote to all US governors asking them to "prioritise aviation frontline workers for allocation of the vaccine in your upcoming implementation plan." The groups noted that "aviation workers are frontline workers who either encounter the traveling public frequently or are required to perform our work in close proximity to our colleagues and perform our jobs onsite." Earlier this month, the FAA sent guidance to airports to prepare for vaccine distribution, including other facilities that may serve as alternate or diversion airports. The FAA said that some aircraft used for vaccine shipments may be larger than the aircraft used for passenger-carrying flights that typically serve that airport and operators may opt to have extra aircraft rescue and firefighting services. (with inputs)

US FAA approves use of Moderna COVID-19 vaccine by pilots

Moderna Inc's coronavirus vaccine on Friday (December 18) became the second to receive emergency use authorization (EUA) from the U.S. Food and Drug Administration, welcome news to a nation with a staggering COVID-19 death toll of over 307,000 lives lost.

US FDA authorizes Moderna's COVID-19 vaccine for emergency use

A panel of outside advisors to the US Food and Drug Administration (FDA) has overwhelmingly endorsed emergency use of Moderna Inc's coronavirus vaccine.

In the US, where 3,249 new deaths were recorded in the last 24 hours alone, emergency approval of the Moderna jab -- the second vaccine allowed in a Western country -- would pave the way for six million doses to potentially start shipping as soon as this weekend.

The US began rolling out the Pfizer jabs on Monday, hoping to have 20 million people immunised in December.

The committee voted 20-0 with one abstention that the benefits of the vaccine outweigh its risks in people aged 18 and older, one week after the same panel backed a similar vaccine from Pfizer Inc and German partner BioNTech SE, leading to an FDA emergency use authorization (EUA) a day later.

The FDA is expected to grant the EUA as early as late Thursday or Friday, providing another ray of hope to a nation that has lost more than 300,000 lives to COVID-19 - including a one-day high of 3,580 deaths on Wednesday - while record numbers of patients threaten to overwhelm US hospitals and healthcare workers.

The one abstention came from Dr Michael Kurilla, who works at the National Institutes of Health and felt blanket authorization for those 18 and older was too broad.

The Moderna vaccine is set to begin distribution as soon as the FDA gives the green light.&nbsp;

Unlike Pfizer's vaccine, which comes with complex distribution challenges due to its need to be shipped and stored at -70 Celsius (-94 F), Moderna's vaccine does not require specialised ultra-cold freezers or vast quantities of dry ice, making it easier to supply rural and remote areas.

The company said on Thursday it has expanded the handling guidance for the vaccine to allow it to be moved locally in a liquid state at standard refrigerated temperatures. In some cases, Moderna said, this could be the only practical way to move it to clinics or remote locations.

The first wave of doses are expected to be earmarked for healthcare workers who treat COVID-19 patients and vulnerable residents and staff of nursing homes.

Documents prepared by FDA scientists and released ahead of the meeting, said a two-dose regimen of the Moderna vaccine was highly effective in preventing COVID-19 and did not raise any specific safety issues.

The vaccine, based on the new technology of synthetic messenger RNA (mRNA), is administered in two shots about 28 days apart. The Pfizer/BioNTech shot is also an mRNA vaccine.

About 20 million doses are expected to be delivered this month, with the rest of the initial purchase coming in the first quarter of next year.

The United States in August entered a $1.5 billion pact with Moderna to acquire 100 million doses of its vaccine.

(with inputs)

A panel of outside advisors to the US Food and Drug Administration (FDA) has overwhelmingly endorsed emergency use of Moderna Inc's coronavirus vaccine. In the US, where 3,249 new deaths were recorded in the last 24 hours alone, emergency approval of the Moderna jab -- the second vaccine allowed in a Western country -- would pave the way for six million doses to potentially start shipping as soon as this weekend.

A panel of outside advisors to the US Food and Drug Administration (FDA) has overwhelmingly endorsed emergency use of Moderna Inc's coronavirus vaccine. In the US, where 3,249 new deaths were recorded in the last 24 hours alone, emergency approval of the Moderna jab -- the second vaccine allowed in a Western country -- would pave the way for six million doses to potentially start shipping as soon as this weekend. The US began rolling out the Pfizer jabs on Monday, hoping to have 20 million people immunised in December. The committee voted 20-0 with one abstention that the benefits of the vaccine outweigh its risks in people aged 18 and older, one week after the same panel backed a similar vaccine from Pfizer Inc and German partner BioNTech SE, leading to an FDA emergency use authorization (EUA) a day later. The FDA is expected to grant the EUA as early as late Thursday or Friday, providing another ray of hope to a nation that has lost more than 300,000 lives to COVID-19 - including a one-day high of 3,580 deaths on Wednesday - while record numbers of patients threaten to overwhelm US hospitals and healthcare workers. The one abstention came from Dr Michael Kurilla, who works at the National Institutes of Health and felt blanket authorization for those 18 and older was too broad. The Moderna vaccine is set to begin distribution as soon as the FDA gives the green light. Unlike Pfizer's vaccine, which comes with complex distribution challenges due to its need to be shipped and stored at -70 Celsius (-94 F), Moderna's vaccine does not require specialised ultra-cold freezers or vast quantities of dry ice, making it easier to supply rural and remote areas. The company said on Thursday it has expanded the handling guidance for the vaccine to allow it to be moved locally in a liquid state at standard refrigerated temperatures. In some cases, Moderna said, this could be the only practical way to move it to clinics or remote locations. The first wave of doses are expected to be earmarked for healthcare workers who treat COVID-19 patients and vulnerable residents and staff of nursing homes. Documents prepared by FDA scientists and released ahead of the meeting, said a two-dose regimen of the Moderna vaccine was highly effective in preventing COVID-19 and did not raise any specific safety issues. The vaccine, based on the new technology of synthetic messenger RNA (mRNA), is administered in two shots about 28 days apart. The Pfizer/BioNTech shot is also an mRNA vaccine. About 20 million doses are expected to be delivered this month, with the rest of the initial purchase coming in the first quarter of next year. The United States in August entered a $1.5 billion pact with Moderna to acquire 100 million doses of its vaccine. (with inputs)

US FDA advisory panel endorses Moderna coronavirus vaccine

The USb FDA has confirmed the safety and efficacy of Moderna’s Covid vaccine, ahead of a meeting on Thursday.

The FDA said the mRNA vaccine is 94.1% effective at preventing coronavirus, confirming earlier results released by the company.

The report came two days before the independent Vaccines and Related Biological Products Advisory Committee meets on Thursday to discuss the safety and efficacy data and vote on recommending emergency use authorisation.

“FDA considers that the totality of available data are sufficient to support an evaluation of this product for EUA,” read a 54-page briefing document from the Food and Drug Administration.

The most common side effects reported in trial participants have been only found to be injection site pain, fatigue, headache, muscle pain, joint pain and chills.

The proposed use of the vaccine is for adults age 18 and older.

The US last week granted the Pfizer coronavirus vaccine emergency use authorisation -- just one day after the VRBPAC meeting, under pressure from President Trump. Doses were then administered on Monday.

The USb FDA has confirmed the safety and efficacy of Moderna’s Covid vaccine, ahead of a meeting on Thursday. The FDA said the mRNA vaccine is 94.1% effective at preventing coronavirus, confirming earlier results released by the company.

The USb FDA has confirmed the safety and efficacy of Moderna’s Covid vaccine, ahead of a meeting on Thursday. The FDA said the mRNA vaccine is 94.1% effective at preventing coronavirus, confirming earlier results released by the company. The report came two days before the independent Vaccines and Related Biological Products Advisory Committee meets on Thursday to discuss the safety and efficacy data and vote on recommending emergency use authorisation. “FDA considers that the totality of available data are sufficient to support an evaluation of this product for EUA,” read a 54-page briefing document from the Food and Drug Administration. The most common side effects reported in trial participants have been only found to be injection site pain, fatigue, headache, muscle pain, joint pain and chills. The proposed use of the vaccine is for adults age 18 and older. The US last week granted the Pfizer coronavirus vaccine emergency use authorisation -- just one day after the VRBPAC meeting, under pressure from President Trump. Doses were then administered on Monday.

US FDA confirms efficacy of Moderna vaccine ahead of Thursday meeting

US experts will meet Thursday to decide whether to recommend approval of Moderna's Covid-19 vaccine for emergency use.

Moderna vaccine inches closer to emergency use approval in United States

Italy has been hit by heavy rain and snowfall that caused landslides, flooding and a high risk of avalanches. In the area of Modena, in Emilia-Romagna, 60 families have been evacuated due to the overflowing of the Panaro river due to heavy rain.

Central Italy hit by severe floods & heavy snowfall

Moderna plans to have 100 to 125 million doses of its Covid-19 vaccine available in the first quarter of 2021, the vast majority of which will go to the United States, the biotechnology company announced Thursday.

Between 85 and 100 million of the doses will be distributed in the United States, with the rest of the world receiving the remaining 15 to 25 million, the Cambridge, Massachusetts-based company said in a statement.

Moderna also confirmed that it expects to have 20 million vaccine doses available in the US by the end of 2020.

The company has been working on its American supply and production chain for months, in preparation for the vaccine's expected emergency approval by US Food and Drug Administration (FDA).

For all countries outside the United States, production will take place in Switzerland.

US officials have said they plan to distribute 40 million vaccine doses by the end of the year, including those produced by Pfizer-BioNTech.

That would mean 20 million people vaccinated by the end of 2020, with each person requiring two doses.

The Moderna vaccine will be reviewed by an advisory committee of the FDA on December 17, and could be green lit for emergency approval soon after.

The FDA advisory committee meeting for the Pfizer-BioNTech vaccine, which was approved Wednesday by Britain for general use, will take place on December 10.

Moderna plans to have 100 to 125 million doses of its Covid-19 vaccine available in the first quarter of 2021, the vast majority of which will go to the United States, the biotechnology company announced Thursday.

Moderna plans to have 100 to 125 million doses of its Covid-19 vaccine available in the first quarter of 2021, the vast majority of which will go to the United States, the biotechnology company announced Thursday. Between 85 and 100 million of the doses will be distributed in the United States, with the rest of the world receiving the remaining 15 to 25 million, the Cambridge, Massachusetts-based company said in a statement. Moderna also confirmed that it expects to have 20 million vaccine doses available in the US by the end of 2020. The company has been working on its American supply and production chain for months, in preparation for the vaccine's expected emergency approval by US Food and Drug Administration (FDA). For all countries outside the United States, production will take place in Switzerland. US officials have said they plan to distribute 40 million vaccine doses by the end of the year, including those produced by Pfizer-BioNTech. That would mean 20 million people vaccinated by the end of 2020, with each person requiring two doses. The Moderna vaccine will be reviewed by an advisory committee of the FDA on December 17, and could be green lit for emergency approval soon after. The FDA advisory committee meeting for the Pfizer-BioNTech vaccine, which was approved Wednesday by Britain for general use, will take place on December 10.

Moderna plans 100 million Covid vaccine doses in early 2021

The United Kingdom has approved a vaccine with the rollout beginning on Monday. Russia is already giving shots to its citizens - but selectively.

The United States wants to start inoculating its citizens before Christmas.

As the world gears up for the vaccines, India has kicked off its own preparations. For the first time today, Indian Prime Minister Narendra Modi outlined India's vaccine strategy.

The priorities for India include preparations and the plan for mass inoculation. The Indian prime minister believes India won't have to wait for long. The vaccine could be ready within weeks.

Prime Minister Modi had visited three vaccine manufacturers last week. The Indian prime minister informed different political leaders about India's preparations and said Indians could get a vaccine within weeks.

"Experts believe that we will not have to wait for the coronavirus vaccine for long. It is believed that in the next few weeks the vaccine will be ready. As soon as we get a green signal from the scientists, the vaccination program will start in India," the Indian prime minister said.

"The Indian scientists are very confident of succeeding; their confidence level is very high. Now we are hearing about the names of several vaccines of other countries in the market but still, the world is keeping a watch on cheaper and the safest vaccine and because of this, it is natural the world is keeping a watch on India as well," PM Modi added.

There are eight vaccine candidates that are on India's radar. They are on different stages of trials and the vaccines can be manufactured in India. There are three vaccine candidates that are made in India. It this means they are being developed in India.

The vaccines are in different stages of trials with the rollout now barely weeks away, India too is laying down a list of priority. The healthcare workers like several other countries will be first to get the shots in India with 10 million health workers first in line to get the vaccine followed by 20 million frontline workers which include police and armed forces personnel and municipal workers among others.

270 million senior citizens will be eligible for the jab too. Those with serious health conditions are likely to be prioritized. A national expert group has been created which includes technical experts as well as officials from the central and the state government.

This group will shoulder the responsibility of India's vaccine campaign. The focus is on vaccines that will be cheap and safe. It is what the world needs to defeat the Wuhan virus. A small group of wealthy countries have already grabbed more than half of the potential doses in the world which includes countries like the United States, the United Kingdom, Japan and Canada.

They have struck deals that ensure large enough supplies to vaccinate their entire populations with doses to spare. In comparison, an alliance of more than 150 countries has only managed to secure 700 million doses consisting of Covax the global alliance for equitable vaccine access that includes several poor countries.

The world will be watching India closely because if it accomplishes its mission to ensure cheap and safe vaccines for all then several countries could reach out to New Delhi for help.

The United Kingdom has approved a vaccine with the rollout beginning on Monday. Russia is already giving shots to its citizens - but selectively. The United States wants to start inoculating its citizens before Christmas.

The United Kingdom has approved a vaccine with the rollout beginning on Monday. Russia is already giving shots to its citizens - but selectively. The United States wants to start inoculating its citizens before Christmas. As the world gears up for the vaccines, India has kicked off its own preparations. For the first time today, Indian Prime Minister Narendra Modi outlined India's vaccine strategy. The priorities for India include preparations and the plan for mass inoculation. The Indian prime minister believes India won't have to wait for long. The vaccine could be ready within weeks. Prime Minister Modi had visited three vaccine manufacturers last week. The Indian prime minister informed different political leaders about India's preparations and said Indians could get a vaccine within weeks. "Experts believe that we will not have to wait for the coronavirus vaccine for long. It is believed that in the next few weeks the vaccine will be ready. As soon as we get a green signal from the scientists, the vaccination program will start in India," the Indian prime minister said. "The Indian scientists are very confident of succeeding; their confidence level is very high. Now we are hearing about the names of several vaccines of other countries in the market but still, the world is keeping a watch on cheaper and the safest vaccine and because of this, it is natural the world is keeping a watch on India as well," PM Modi added. There are eight vaccine candidates that are on India's radar. They are on different stages of trials and the vaccines can be manufactured in India. There are three vaccine candidates that are made in India. It this means they are being developed in India. The vaccines are in different stages of trials with the rollout now barely weeks away, India too is laying down a list of priority. The healthcare workers like several other countries will be first to get the shots in India with 10 million health workers first in line to get the vaccine followed by 20 million frontline workers which include police and armed forces personnel and municipal workers among others. 270 million senior citizens will be eligible for the jab too. Those with serious health conditions are likely to be prioritized. A national expert group has been created which includes technical experts as well as officials from the central and the state government. This group will shoulder the responsibility of India's vaccine campaign. The focus is on vaccines that will be cheap and safe. It is what the world needs to defeat the Wuhan virus. A small group of wealthy countries have already grabbed more than half of the potential doses in the world which includes countries like the United States, the United Kingdom, Japan and Canada. They have struck deals that ensure large enough supplies to vaccinate their entire populations with doses to spare. In comparison, an alliance of more than 150 countries has only managed to secure 700 million doses consisting of Covax the global alliance for equitable vaccine access that includes several poor countries. The world will be watching India closely because if it accomplishes its mission to ensure cheap and safe vaccines for all then several countries could reach out to New Delhi for help.

Why the world is looking at India for coronavirus vaccine rollout

Researchers at the National Institute for Allergies and Infectious Diseases which co-developed the drug, studied the immune response of 34 adult participants, young and old, from the first stage of a clinical trial.

Study shows Moderna vaccine confers at least 3 months immunity

The United States is expecting to give <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine </a>to about 100 million people by the end of February 2021, a top official said on Wednesday.&nbsp;

The vaccination is likely to begin in the US within weeks once Pfizer-BioNTech and Moderna-NIH get approval.&nbsp;

Watch |

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-uk-approves-pfizer-vaccine-347037/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

&nbsp;"Between mid-December, and the end of February, we will have potentially immunised 100 million people," said Moncef Slaoui, scientific advisor to the US administration's Operation Warp Speed (OWS) program, as quoted by news agency AFP.

Also read | <a href="https://www.wionews.com/world/vaccines-insufficient-to-prevent-surge-in-coronavirus-for-next-six-months-who-347022">Vaccines insufficient to prevent surge in coronavirus for next six months: WHO</a>&nbsp;&nbsp; &nbsp;

If the US achieves this target, it will cover about 40 per cent of the US's adult population.&nbsp;

Slaoui also said that the goal of immunising 100 million people will cover the people "at-risk" that includes first responders, health care professionals and elderly.&nbsp;

There will an "ample" amount of Covid-19 vaccine in December for three million people from long-term care facilities, he added.&nbsp;

The remaining vaccination of the first tranche would be enough to cover the majority of the health care workers if states and other regions agree with federal recommendations to prioritize this group of people.&nbsp;

As many as 20 million people in the US will be immunised in December, 30 million and 50 million in January and February respectively.&nbsp;

However, this figure does not include vaccine developed by Johnson &amp; Johnson and Oxford-AstraZeneca that are in the late-stage trials.&nbsp;

Meanwhile, Pfizer-BioNTech vaccine was approved by the United Kingdom on Wednesday.&nbsp;

The US FDA will hold a public meeting of an advisory group on December 10 for Pfizer's vaccine and on December 17 for Moderna's drug following which it will be decided whether to grant an emergency use authorization (EUA) or not.&nbsp;

 
&nbsp;

The United States is expecting to give coronavirus vaccine to about 100 million people by the end of February 2021, a top official said on Wednesday. The vaccination is likely to begin in the US within weeks once Pfizer-BioNTech and Moderna-NIH get approval.

The United States is expecting to give coronavirus vaccine to about 100 million people by the end of February 2021, a top official said on Wednesday. The vaccination is likely to begin in the US within weeks once Pfizer-BioNTech and Moderna-NIH get approval. Watch | "Between mid-December, and the end of February, we will have potentially immunised 100 million people," said Moncef Slaoui, scientific advisor to the US administration's Operation Warp Speed (OWS) program, as quoted by news agency AFP. Also read | Vaccines insufficient to prevent surge in coronavirus for next six months: WHO If the US achieves this target, it will cover about 40 per cent of the US's adult population. Slaoui also said that the goal of immunising 100 million people will cover the people "at-risk" that includes first responders, health care professionals and elderly. There will an "ample" amount of Covid-19 vaccine in December for three million people from long-term care facilities, he added. The remaining vaccination of the first tranche would be enough to cover the majority of the health care workers if states and other regions agree with federal recommendations to prioritize this group of people. As many as 20 million people in the US will be immunised in December, 30 million and 50 million in January and February respectively. However, this figure does not include vaccine developed by Johnson & Johnson and Oxford-AstraZeneca that are in the late-stage trials. Meanwhile, Pfizer-BioNTech vaccine was approved by the United Kingdom on Wednesday. The US FDA will hold a public meeting of an advisory group on December 10 for Pfizer's vaccine and on December 17 for Moderna's drug following which it will be decided whether to grant an emergency use authorization (EUA) or not.

US to immunise 100 million people by February: Top official

The federal government is distributing the vaccines based on a state’s population. Cuomo said an estimated 40,000 more doses of Moderna’s vaccine are expected by the end of the month

1st batch of 170,000 doses to arrive in New York by Dec 15

The US company is submitting the data to the regulators in the US, Europe and the UK for an emergency licence.

A turning point in the COVID-19 Pandemic as Moderna claims 100% efficacy in severe cases

Biotechnology company Moderna said on Monday that it will request the US and European regulators to issue an emergency authorisation for its coronavirus vaccine, which it said is 100 per cent effective against severe COVID-19 cases.

Moderna said the primary efficacy analysis of the Phase-3 study of its vaccine candidate mRNA-1273 conducted on 196 cases indicates a vaccine efficacy of 94.1 per cent.

While the vaccine efficacy against COVID-19 was 94.1 per cent, vaccine efficacy against severe COVID-19 was 100 per cent, the company said.

Moderna plans to request an Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA) for the vaccine.

"This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease.

We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalisations and death," Chief Executive Officer of Moderna Stéphane Bancel said.

Bancel said the company "will file today for an Emergency Use Authorisation from the FDA and continue forging ahead with the rolling reviews that have already been initiated with several regulatory agencies around the globe." Moderna anticipates that the shipping of the vaccine to designated distribution points throughout the US will occur shortly after an Emergency Use Authorisation is granted.

Moderna will also submit an application for Conditional Marketing Authorisation (CMA) with the European Medicines Agency (EMA).

The company has already initiated the rolling review process with other global regulatory bodies such as Health Canada, SwissMedic, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), Ministry of Health in Israel, and Health Sciences Authority in Singapore and intends to seek Prequalification (PQ) and/or Emergency Use Listing (EUL) with the World Health Organisation (WHO).

The Phase 3 study, known as the COVE study, enrolled more than 30,000 participants in the US and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services.

The company said efficacy was consistent across age, race and ethnicity, and gender demographics.

The 196 COVID-19 cases included 33 older adults (ages 65+) and 42 participants identifying as being from diverse communities (including 29 Hispanic or LatinX, 6 Black or African Americans, 4 Asian Americans and 3 multiracial participants).

Based on prior analysis, the most common side effects included injection site pain, fatigue, headache, and redness at the injection site.

The company will submit data from the Phase 3 COVE study to a peer-reviewed publication.

Moderna is working with the US CDC and other authorities and global stakeholders to be prepared for the distribution of the vaccine in the event that it receives a EUA and similar global authorisations and approvals.

By the end of 2020, the Company expects to have approximately 20 million doses of the vaccine available in the US and remains on track to manufacture 500 million to 1 billion doses globally in 2021.

Biotechnology company Moderna said on Monday that it will request the US and European regulators to issue an emergency authorisation for its coronavirus vaccine, which it said is 100 per cent effective against severe COVID-19 cases.

Biotechnology company Moderna said on Monday that it will request the US and European regulators to issue an emergency authorisation for its coronavirus vaccine, which it said is 100 per cent effective against severe COVID-19 cases. Moderna said the primary efficacy analysis of the Phase-3 study of its vaccine candidate mRNA-1273 conducted on 196 cases indicates a vaccine efficacy of 94.1 per cent. While the vaccine efficacy against COVID-19 was 94.1 per cent, vaccine efficacy against severe COVID-19 was 100 per cent, the company said. Moderna plans to request an Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA) for the vaccine. "This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalisations and death," Chief Executive Officer of Moderna Stéphane Bancel said. Bancel said the company "will file today for an Emergency Use Authorisation from the FDA and continue forging ahead with the rolling reviews that have already been initiated with several regulatory agencies around the globe." Moderna anticipates that the shipping of the vaccine to designated distribution points throughout the US will occur shortly after an Emergency Use Authorisation is granted. Moderna will also submit an application for Conditional Marketing Authorisation (CMA) with the European Medicines Agency (EMA). The company has already initiated the rolling review process with other global regulatory bodies such as Health Canada, SwissMedic, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), Ministry of Health in Israel, and Health Sciences Authority in Singapore and intends to seek Prequalification (PQ) and/or Emergency Use Listing (EUL) with the World Health Organisation (WHO). The Phase 3 study, known as the COVE study, enrolled more than 30,000 participants in the US and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services. The company said efficacy was consistent across age, race and ethnicity, and gender demographics. The 196 COVID-19 cases included 33 older adults (ages 65+) and 42 participants identifying as being from diverse communities (including 29 Hispanic or LatinX, 6 Black or African Americans, 4 Asian Americans and 3 multiracial participants). Based on prior analysis, the most common side effects included injection site pain, fatigue, headache, and redness at the injection site. The company will submit data from the Phase 3 COVE study to a peer-reviewed publication. Moderna is working with the US CDC and other authorities and global stakeholders to be prepared for the distribution of the vaccine in the event that it receives a EUA and similar global authorisations and approvals. By the end of 2020, the Company expects to have approximately 20 million doses of the vaccine available in the US and remains on track to manufacture 500 million to 1 billion doses globally in 2021.

Moderna vaccine 100% effective in severe cases; to seek US, EU approval

After almost a year of the world fighting against the coronavirus pandemic, governments and pharmaceutical companies are rushing to roll out the <a href="https://www.wionews.com/topics/coronavirus-vaccine">COVID-19 vaccines</a> and put an end to this pandemic.

In a bid to save people from the pandemic, the US-based company Moderna has revealed that the experts are hoping to roll out the vaccine for the general public before the end of the year.

Also read|&nbsp;<a href="https://www.wionews.com/world/leaked-documents-show-china-bluntly-lied-about-covid-19-and-mishandled-early-pandemic-346590" hreflang="en">Leaked documents show China bluntly lied about Covid-19 and mishandled early pandemic</a>

Moderna revealed that the company is filing&nbsp;for emergency authorisation of its vaccine in the United States and Europe on Monday. This has also come with the warning of a "surge superimposed on the surge" in the US in December.

The news has come after&nbsp;Pfizer and Germany’s BioNTech also applied for similar approvals last week with the hope of getting approval by the middle of the December.

Also read|&nbsp;<a href="https://www.wionews.com/world/moderna-vaccine-100-effective-in-severe-cases-to-seek-us-eu-approval-346574" hreflang="en">Moderna vaccine 100% effective in severe cases; to seek US, EU approval</a>

"We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic," said Moderna CEO Stephane Bancel.

Health Secretary Alex Azar, too, said he hopes the people of the US will be able to have access tot he vaccines by Christmas time. "We could be seeing both of these vaccines out and getting into people’s arms before Christmas.," he told local media.

Also read|&nbsp;<a href="https://www.wionews.com/world/russian-hospital-claims-to-have-administered-sputnik-v-to-civilians-last-week-346522" hreflang="en">Russian hospital claims to have administered Sputnik V to civilians last week</a>

Meanwhile, Anthony Fauci has urged people to exercise caution as the cases are expected to increase significantly following the holiday season, which started with Thanksgiving Day in the last week. "What we expect, unfortunately, as we go for the next couple of weeks into December is that we might see a surge superimposed on the surge we are already in," he told local media.

After almost a year of the world fighting against the coronavirus pandemic, governments and pharmaceutical companies are rushing to roll out the COVID-19 vaccines and put an end to this pandemic.

After almost a year of the world fighting against the coronavirus pandemic, governments and pharmaceutical companies are rushing to roll out the COVID-19 vaccines and put an end to this pandemic. In a bid to save people from the pandemic, the US-based company Moderna has revealed that the experts are hoping to roll out the vaccine for the general public before the end of the year. Also read| Leaked documents show China bluntly lied about Covid-19 and mishandled early pandemic Moderna revealed that the company is filing for emergency authorisation of its vaccine in the United States and Europe on Monday. This has also come with the warning of a "surge superimposed on the surge" in the US in December. The news has come after Pfizer and Germany’s BioNTech also applied for similar approvals last week with the hope of getting approval by the middle of the December. Also read| Moderna vaccine 100% effective in severe cases; to seek US, EU approval "We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic," said Moderna CEO Stephane Bancel. Health Secretary Alex Azar, too, said he hopes the people of the US will be able to have access tot he vaccines by Christmas time. "We could be seeing both of these vaccines out and getting into people’s arms before Christmas.," he told local media. Also read| Russian hospital claims to have administered Sputnik V to civilians last week Meanwhile, Anthony Fauci has urged people to exercise caution as the cases are expected to increase significantly following the holiday season, which started with Thanksgiving Day in the last week. "What we expect, unfortunately, as we go for the next couple of weeks into December is that we might see a surge superimposed on the surge we are already in," he told local media.

US predicts availability of COVID-19 ‘vaccines before Christmas’

Moderna Inc will apply for US&nbsp;and European emergency authorisation for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns, the company said. 
&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/moderna-to-charge-25-37-for-covid-19-vaccine-says-ceo-344712/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Moderna also reported that the vaccine`s efficacy rate was consistent across age, race, ethnicity and gender demographics as well as having a 100% success rate in preventing severe cases of a disease that has killed nearly 1.5 million people.

&nbsp;

Also read:&nbsp;<a href="http://13.235.153.162/world/sputnik-v-takes-a-jibe-at-pfizer-moderna-covid-19-vaccine-claims-own-drug-much-cheaper-344895" hreflang="en">Sputnik V takes a jibe at Pfizer, Moderna Covid-19 vaccine prices, claims own drug much cheaper</a> 
 
The filing sets Moderna`s product up to be the second vaccine likely to receive U.S. emergency use authorization this year following a shot developed by Pfizer and BioNTech which had a 95% efficacy rate in trials. 
 
"We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it," Moderna Chief Medical Officer Tal Zaks said. "We expect to be playing a major part in turning around this pandemic." 
 
Of the 196 volunteers who contracted COVID-19 in the trial with more than 30,000 people, 185 received a placebo while 11 got the vaccine. Moderna reported 30 severe cases - all in the placebo group - which means the vaccine was 100% effective in preventing severe cases. 
 
"As the numbers of cases reported grows, confidence grows that this amazing protection will be maintained in a product that can be rolled out to protect the public," said Alexander Edwards, associate professor in biomedical technology at Britain`s University of Reading. 
 
In addition to filing its U.S. application, Moderna said it would seek conditional approval from the European Medicines Agency, which has already begun a rolling review of its data, and would continue to talk with other regulators.

Also read:&nbsp;<a href="http://13.235.153.162/world/recipharm-to-produce-some-of-modernas-covid-19-vaccine-in-france-345283" hreflang="en">Recipharm to produce some of Moderna's COVID-19 vaccine in France</a> 
 
Pfizer has already applied for emergency use authorization in the United States and Europe, putting it about a week ahead of Moderna. 
 
Moderna said it was on track to have about 20 million doses of its vaccine ready to ship in the United States by the end of 2020, enough to inoculate 10 million people. 
 
`JUST OVERWHELMING` 
 
Both of the vaccines use a new technology called synthetic messenger RNA (mRNA) whereas others, such as Britain`s AstraZeneca, are using more traditional methods to develop their vaccines. 
 
AstraZeneca has announced an average efficacy rate of 70% for its shot and as much as 90% for a subgroup of trial participants who got a half dose, followed by a full dose. But some scientists have expressed doubts about the robustness of the 90% efficacy figure for the smaller group. 
 
Moderna`s latest efficacy result is slightly lower than an interim analysis released on Nov. 16 of 94.5% effectiveness, a difference that Zaks said was not statistically significant. 
 
"At this level of effectiveness, when you just do the math of what it means for the pandemic that`s raging around us, it`s just overwhelming," said Zaks, who said he cried when he saw the final results over the weekend. 
 
Both the Moderna and Pfizer vaccines proved more effective than anticipated and were far superior to the 50% benchmark set by the U.S. Food and Drug Administration (FDA). 
 
The past few weeks of positive vaccine results have ignited hopes for an end to a pandemic that has battered economies and comes as new infections and COVID-19 hospitalizations are at record levels across the United States. 
 
Independent advisers to the FDA are scheduled to meet on Dec. 17 to review Moderna`s trial data and make a recommendation to the FDA. They will meet on Dec. 10 to review Pfizer`s data. 
 
Shortly after gaining emergency use authorization, Moderna expects the vaccine to be shipped to distribution points throughout the United States by the government`s Operation Warp Speed program and McKesson Corp, a drug distributor contracted by the U.S. government. 
 
Its distribution is expected to be easier than Pfizer`s because while it needs to be stored in a freezer, it does not require the ultra-cold temperature needed by Pfizer`s vaccine. 
 
 
CONSISTENT ACROSS AGE AND ETHNICITY 
 
Moderna said the 196 COVID-19 cases in its trial included 33 adults over 65 years old and 42 volunteers from racially diverse groups, including 29 Latinos, 6 Blacks, 4 Asian Americans and 3 multiracial participants. There was one death related to COVID-19 in the placebo group. 
 
Azra Ghani, chair in infectious disease epidemiology at Imperial College London, said Monday`s details from Moderna confirmed the vaccine was highly efficient, including against severe cases. 
 
"Whilst this does not exclude some risk of severe disease after vaccination given the relatively small number of severe cases, these results suggest very high efficacy," she said. 
 
Zaks said the vaccine has been developed during a period of "political acrimony" and having a highly effective vaccine may go a long way toward erasing some of that distrust. 
 
"This is as black and white as an effect on a population will be. Your chances of actually being sick if you`ve been vaccinated are decreased 20-fold," he said. 
 
Moderna reported no new side effects since its interim analysis. Based on that analysis, the most common side effects were fatigue, injection site redness and pain, headache and body aches, which rose after the second dose and were short-lived. 
 
Zaks said the vaccine caused significant flu-like symptoms in some participants, which, he said, "goes hand-in-hand with having such a potent vaccine." But it has not caused any significant safety concerns so far. 
 
Moderna plans to start a new trial to test the vaccine in adolescents before the end of the year, followed by another in even younger volunteers early in 2021. It hopes to have the vaccine available for adolescents by September, Zaks said. 
 
Other vaccine makers have said they are studying their vaccines in young people as well.

Moderna Inc will apply for US and European emergency authorisation for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.

Moderna Inc will apply for US and European emergency authorisation for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns, the company said. Moderna also reported that the vaccine`s efficacy rate was consistent across age, race, ethnicity and gender demographics as well as having a 100% success rate in preventing severe cases of a disease that has killed nearly 1.5 million people. Also read: Sputnik V takes a jibe at Pfizer, Moderna Covid-19 vaccine prices, claims own drug much cheaper The filing sets Moderna`s product up to be the second vaccine likely to receive U.S. emergency use authorization this year following a shot developed by Pfizer and BioNTech which had a 95% efficacy rate in trials. "We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it," Moderna Chief Medical Officer Tal Zaks said. "We expect to be playing a major part in turning around this pandemic." Of the 196 volunteers who contracted COVID-19 in the trial with more than 30,000 people, 185 received a placebo while 11 got the vaccine. Moderna reported 30 severe cases - all in the placebo group - which means the vaccine was 100% effective in preventing severe cases. "As the numbers of cases reported grows, confidence grows that this amazing protection will be maintained in a product that can be rolled out to protect the public," said Alexander Edwards, associate professor in biomedical technology at Britain`s University of Reading. In addition to filing its U.S. application, Moderna said it would seek conditional approval from the European Medicines Agency, which has already begun a rolling review of its data, and would continue to talk with other regulators. Also read: Recipharm to produce some of Moderna's COVID-19 vaccine in France Pfizer has already applied for emergency use authorization in the United States and Europe, putting it about a week ahead of Moderna. Moderna said it was on track to have about 20 million doses of its vaccine ready to ship in the United States by the end of 2020, enough to inoculate 10 million people. `JUST OVERWHELMING` Both of the vaccines use a new technology called synthetic messenger RNA (mRNA) whereas others, such as Britain`s AstraZeneca, are using more traditional methods to develop their vaccines. AstraZeneca has announced an average efficacy rate of 70% for its shot and as much as 90% for a subgroup of trial participants who got a half dose, followed by a full dose. But some scientists have expressed doubts about the robustness of the 90% efficacy figure for the smaller group. Moderna`s latest efficacy result is slightly lower than an interim analysis released on Nov. 16 of 94.5% effectiveness, a difference that Zaks said was not statistically significant. "At this level of effectiveness, when you just do the math of what it means for the pandemic that`s raging around us, it`s just overwhelming," said Zaks, who said he cried when he saw the final results over the weekend. Both the Moderna and Pfizer vaccines proved more effective than anticipated and were far superior to the 50% benchmark set by the U.S. Food and Drug Administration (FDA). The past few weeks of positive vaccine results have ignited hopes for an end to a pandemic that has battered economies and comes as new infections and COVID-19 hospitalizations are at record levels across the United States. Independent advisers to the FDA are scheduled to meet on Dec. 17 to review Moderna`s trial data and make a recommendation to the FDA. They will meet on Dec. 10 to review Pfizer`s data. Shortly after gaining emergency use authorization, Moderna expects the vaccine to be shipped to distribution points throughout the United States by the government`s Operation Warp Speed program and McKesson Corp, a drug distributor contracted by the U.S. government. Its distribution is expected to be easier than Pfizer`s because while it needs to be stored in a freezer, it does not require the ultra-cold temperature needed by Pfizer`s vaccine. CONSISTENT ACROSS AGE AND ETHNICITY Moderna said the 196 COVID-19 cases in its trial included 33 adults over 65 years old and 42 volunteers from racially diverse groups, including 29 Latinos, 6 Blacks, 4 Asian Americans and 3 multiracial participants. There was one death related to COVID-19 in the placebo group. Azra Ghani, chair in infectious disease epidemiology at Imperial College London, said Monday`s details from Moderna confirmed the vaccine was highly efficient, including against severe cases. "Whilst this does not exclude some risk of severe disease after vaccination given the relatively small number of severe cases, these results suggest very high efficacy," she said. Zaks said the vaccine has been developed during a period of "political acrimony" and having a highly effective vaccine may go a long way toward erasing some of that distrust. "This is as black and white as an effect on a population will be. Your chances of actually being sick if you`ve been vaccinated are decreased 20-fold," he said. Moderna reported no new side effects since its interim analysis. Based on that analysis, the most common side effects were fatigue, injection site redness and pain, headache and body aches, which rose after the second dose and were short-lived. Zaks said the vaccine caused significant flu-like symptoms in some participants, which, he said, "goes hand-in-hand with having such a potent vaccine." But it has not caused any significant safety concerns so far. Moderna plans to start a new trial to test the vaccine in adolescents before the end of the year, followed by another in even younger volunteers early in 2021. It hopes to have the vaccine available for adolescents by September, Zaks said. Other vaccine makers have said they are studying their vaccines in young people as well.

Moderna seeks US, EU authorisation for vaccine as final results confirm 94% efficacy

Sweden`s Recipharm will produce doses of Moderna`s COVID-19 vaccine candidate in central France, the company said on Wednesday, adding it had started recruiting and investing to start manufacturing.

Recipharm, a contract development and manufacturing organisation (CDMO) that has four plants in France, said it had signed a letter of intent with the U.S. company and that it was expecting a final agreement to be reached next month.

The doses would be produced at Recipharm`s facility in Monts. 
Financial details were not disclosed.

The European Union struck a deal on Tuesday for up to 160 million doses of Moderna`s vaccine candidate, taking the bloc`s potential stock of COVID-19 shots to nearly 2 billion.

Last week, Moderna said its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial.

There is no internationally approved vaccine yet to prevent COVID-19 caused by the new coronavirus which has killed more than 1.4 million people and derailed the world economy.

Sweden`s Recipharm will produce doses of Moderna`s COVID-19 vaccine candidate in central France, the company said on Wednesday, adding it had started recruiting and investing to start manufacturing.

Sweden`s Recipharm will produce doses of Moderna`s COVID-19 vaccine candidate in central France, the company said on Wednesday, adding it had started recruiting and investing to start manufacturing. Recipharm, a contract development and manufacturing organisation (CDMO) that has four plants in France, said it had signed a letter of intent with the U.S. company and that it was expecting a final agreement to be reached next month. The doses would be produced at Recipharm`s facility in Monts. Financial details were not disclosed. The European Union struck a deal on Tuesday for up to 160 million doses of Moderna`s vaccine candidate, taking the bloc`s potential stock of COVID-19 shots to nearly 2 billion. Last week, Moderna said its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial. There is no internationally approved vaccine yet to prevent COVID-19 caused by the new coronavirus which has killed more than 1.4 million people and derailed the world economy.

Recipharm to produce some of Moderna's COVID-19 vaccine in France

Reacting on the pricing of two coronavirus vaccine candidates Pfizer and Moderna that has recently shown encouraging results from their human trials, Russia's Sputnik V has said that its prices would be "much lower".

Sputnik V is what Russia claims to be the world's first <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine</a>, but experts have not yet given nod to the drug.&nbsp;

Also read | <a href="https://www.wionews.com/world/oxford-astrazeneca-covid-19-vaccine-shows-70-efficacy-can-be-90-effective-trial-data-reveals-344807">Oxford-AstraZeneca Covid-19 vaccine shows 70% efficacy; can be 90% effective, trial data reveals</a>

It was reacting to a report that quoted Moderna CEO on the price of the vaccine, suggesting that the actual prices of Moderna and Pfizer's vaccine would be much higher and its own drug will be very cheap.&nbsp;

Also read | <a href="wionews.com/world/covid-vaccine-could-reach-first-americans-by-december-11-top-health-official-344800">Covid vaccine could reach first Americans by December 11: Top health official</a>

"Translating pharma lingo: the announced price of Pfizer of $19.50 and Moderna of $25-$37 per dose actually means their price of $39 and $50-$74 per person. Two doses are required per person for the Pfizer, Sputnik V and Moderna vaccines. The price of Sputnik V will be much lower," the Russian vaccine said.&nbsp;

About two weeks ago, Sputnik V's developers claimed that the initial trial results have found the vaccine to be 92 per cent effective.&nbsp;

"The Sputnik V vaccine had an efficacy rate of 92 per cent after the second dose," the statement by Russia's health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said. &nbsp;

Presently, the third and final phase trials of the potential Covid-19 vaccine is undergoing in 29 medical centres across the world in which 42,000 volunteers have participated.

 
&nbsp;

Reacting on the pricing of two coronavirus vaccine candidates Pfizer and Moderna that has recently shown encouraging results from their human trials, Russia's Sputnik V has said that its prices would be "much lower".

Reacting on the pricing of two coronavirus vaccine candidates Pfizer and Moderna that has recently shown encouraging results from their human trials, Russia's Sputnik V has said that its prices would be "much lower". Sputnik V is what Russia claims to be the world's first coronavirus vaccine, but experts have not yet given nod to the drug. Also read | Oxford-AstraZeneca Covid-19 vaccine shows 70% efficacy; can be 90% effective, trial data reveals It was reacting to a report that quoted Moderna CEO on the price of the vaccine, suggesting that the actual prices of Moderna and Pfizer's vaccine would be much higher and its own drug will be very cheap. Also read | Covid vaccine could reach first Americans by December 11: Top health official "Translating pharma lingo: the announced price of Pfizer of $19.50 and Moderna of $25-$37 per dose actually means their price of $39 and $50-$74 per person. Two doses are required per person for the Pfizer, Sputnik V and Moderna vaccines. The price of Sputnik V will be much lower," the Russian vaccine said. About two weeks ago, Sputnik V's developers claimed that the initial trial results have found the vaccine to be 92 per cent effective. "The Sputnik V vaccine had an efficacy rate of 92 per cent after the second dose," the statement by Russia's health ministry, the state-run Gamaleya research centre and the Russian Direct Investment Fund (RDIF) said. Presently, the third and final phase trials of the potential Covid-19 vaccine is undergoing in 29 medical centres across the world in which 42,000 volunteers have participated.

Sputnik V takes a jibe at Pfizer, Moderna Covid-19 vaccine prices, claims own drug much cheaper

“Our vaccine, therefore, costs about the same as a flu shot, which is between $10 and $50,” he was quoted as saying.

Moderna to charge $25-$37 for COVID-19 vaccine, says CEO

moderna

Moderna, News on Moderna, stories on Moderna, articles on Moderna, Moderna stories at Wion, Moderna news, Moderna latest news